[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584474":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":23,"studyPopulation":24,"armGroups":19,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":49,"collaborators":53,"id":57,"slug":19,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":19,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":19,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":19,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":38,"whyStopped":19,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":19},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of positive anti-HDV","Primary endpoint is seroprevalence rate of positive anti-HDV","at screening",[14,16],{"measure":15,"description":15,"timeFrame":12},"Prevalence rate of detectable HDV RNA",{"measure":17,"description":18,"timeFrame":12},"Prevalence rate of compensated advanced chronic liver disease","Prevalence rate of compensated advanced chronic liver disease (cACLD) defined as a liver stiffness measurement above 10.0 kPa",null,{"allocation":19,"interventionModel":19,"interventionModelDescription":19,"primaryPurpose":19,"observationalModel":21,"timePerspective":22,"maskingInfo":19},"COHORT","PROSPECTIVE","Chronic hepatitis B virus (HBV) infection remains endemic in Hong Kong with an estimated prevalence of 6.2% in the recent Population Health Survey 2020-2022.1 The estimated prevalence of chronic HBV infection among individuals living with HIV is 8%.2 Yet, no data are available concerning the disease burden of hepatitis delta virus (HDV) among individuals living with HIV\u002FHBV coinfection.","Individuals living with HIV\u002FHBV coinfection and HBV-related HCC",[26],{"name":27,"affiliation":5,"role":28},"Lai Hung Grace Wong","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":19,"email":34},"Angel Chim","CONTACT","+85235054205","angelchim@cuhk.edu.hk",[36],{"facility":37,"status":38,"city":39,"state":19,"zip":19,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Chinese University of Hong Kong","RECRUITING","Hong Kong","HK",{"type":42,"coordinates":43},"Point",[44,45],114.17469,22.27832,{"lat":45,"lon":44},[48],{"name":31,"role":32,"phone":33,"phoneExt":19,"email":34},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Grace Lai Hung Wong","Professor",[54],{"name":55,"class":56},"Gilead Sciences","INDUSTRY","100584474",false,"NCT06889805","HDV Screening Study","Universal Screening for Hepatitis Delta Virus (HDV) in Individuals Living with HIV\u002FHBV Coinfection and HBV-related HCC","Inclusion Criteria:\n\n1. Individuals with HIV infection, i.e. anti-HIV or HIV RNA positive; AND\n2. Individuals with chronic hepatitis B, i.e. hepatitis B surface antigen (HBsAg) or HBV DNA positive for two times at least 6 months apart; AND\n3. Aged 18 years old or above.\n4. Written or verbal consent obtained\n\nExclusion Criteria:\n\n1. Refusal to consent\n2. Age \\\u003C 18 years","ALL","18 Years",{"count":66,"type":67},300,"ESTIMATED","OBSERVATIONAL","This is a territory-wide cross-sectional study of all individuals living with HIV\u002FHBV coinfection and HBV-related HCC.",[71],"Hepatitis D Virus Infection",[73],"HDV","2025-03-20",{"date":76,"type":77},"2025-03-24","ACTUAL",{"date":79,"type":77},"2025-02-15",{"date":81,"type":67},"2029-02-17",{"name":51,"class":6},1]